News You Should Know: 3 Takeaways from Top Managed Care Articles June

ICER adds a more formal process to evaluate the diversity of clinical trials and an assessment of a product’s impact on patient and caregiver productivity. ICER also plans to evaluate how newer methods — which would consider the change of a drug’s price over time and disease severity — can be applied to its value assessment.

Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center.

Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.

In this week’s episode of "Tuning In to the C-Suite," Briana Contreras, editor of Managed Healthcare Executive, spoke with Ramin Bastani, CEO of Healthvana.

Cindy Gaines, MSN, RN, chief clinical transformation officer at Lumeon, addresses the current status of electronic health records in the healthcare industry and how automation is filling in its gaps through technology.

Interoperability has been an aspiration in the healthcare IT world for many years. The finalization of new rules means they finally have a chance to prove its merits.